You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》中金降石藥(01093.HK)目標價至11.7元 評級「跑贏行業」
阿思達克 05-27 14:55
中金發表評級報告表示,石藥(01093.HK)今年首季收入按年增16.9%至78.7億元人民幣、扣非淨利潤15.4億元人民幣,均符合該行預期,由於以公允價值計入損益的金融資產公允價值虧損1.3億元人民幣,其純利錄得按年跌4.6%至14億元人民幣,略低於該行預期。 該行表示,看好石藥核心產品放量,將公司今年及明年收入預測分別上調3%至323億元及3%至355億元,而考慮價格壓力及研發費用上升等因素,維持盈利預測基本不變。 中金表示,將石藥目標價下調7%至11.7元,相當於今明兩年預測市盈率各19.6倍及18倍,維持其評級為「跑贏行業」。(ca/w) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account